Literature DB >> 31777095

Guidelines of the Brazilian Society of Oncologic Surgery for pelvic exenteration in the treatment of cervical cancer.

Gustavo A Laporte1, Lucas A G Zanini1, Paulo H Zanvettor1, Alexandre F Oliveira1, Enio Bernado1, Fernando Lissa1, Manoel J P Coelho1, Reitan Ribeiro1, Raphael L C Araujo1, Abner J J Barrozo1, Alexandre F da Costa1, Amario P de Barros Júnior1, Andre Lopes1, Antônio P M Santos1, Bruno R B Azevedo1, Bruno J Q Sarmento1, Carlos A M Marins1, Carlos M B Loureiro1, Cezar A V Galhardo1, Charles N Gatelli1, Claudio A Quadros1, Cláudio V Pinto1, Diego N A O Uchôa1, Diogo R S Martins1, Eduardo Doria-Filho1, Ellen K M A Ribeiro1, Eric R F Pinto1, Evandro A S Dos Santos1, Francisco A M Gozi1, Francisco C Nascimento1, Francisco G Fernandes1, Francisco K L Gomes1, Geraldo J S Nascimento1, Guilherme O Cucolicchio1, Guilherme F Ritt1, Guilherme G de Oliveira1, Gunther P Ayala1, Gustavo C Guimarães1, Gustavo C Ianaze1, Gustavo A Gobetti1, Gustavo M Medeiros1, Gustavo Z Güth1, Heládio F C Neto1, Higino F Figueiredo1, João C Simões1, José C Ferrari1, José P R Furtado1, Leonardo J Vieira1, Lucas F Pereira1, Luiz C F de Almeida1, Muhamed R A Tayeh1, Pedro H M Figueiredo1, Rafael S A V Pereira1, Ramon O Macedo1, Raquel M M Sacramento1, Rayane M Cardoso1, Renato M Zanatto1, Rodrigo A M Martinho1, Rodrigo G Araújo1, Rodrigo N Pinheiro1, Rosilene J Reis1, Sergio B S Goiânia1, Sergio R P Costa1, Tariane F Foiato1, Tyrone C Silva1, Vandré C G Carneiro1, Viviane R Oliveira1, William A Casteleins1.   

Abstract

BACKGROUND AND OBJECTIVES: The primary treatment for locally advanced cases of cervical cancer is chemoradiation followed by high-dose brachytherapy. When this treatment fails, pelvic exenteration (PE) is an option in some cases. This study aimed to develop recommendations for the best management of patients with cervical cancer undergoing salvage PE.
METHODS: A questionnaire was administered to all members of the Brazilian Society of Surgical Oncology. Of them, 68 surgeons participated in the study and were divided into 10 working groups. A literature review of studies retrieved from the National Library of Medicine database was carried out on topics chosen by the participants. These topics were indications for curative and palliative PE, preoperative and intraoperative evaluation of tumor resectability, access routes and surgical techniques, PE classification, urinary, vaginal, intestinal, and pelvic floor reconstructions, and postoperative follow-up. To define the level of evidence and strength of each recommendation, an adapted version of the Infectious Diseases Society of America Health Service rating system was used.
RESULTS: Most conducts and management strategies reviewed were strongly recommended by the participants.
CONCLUSIONS: Guidelines outlining strategies for PE in the treatment of persistent or relapsed cervical cancer were developed and are based on the best evidence available in the literature.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  cervical cancer; pelvic exenteration; surgery; treatment

Mesh:

Year:  2019        PMID: 31777095     DOI: 10.1002/jso.25759

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  2 in total

1.  Staging, recurrence and follow-up of uterine cervical cancer using MRI: Updated Guidelines of the European Society of Urogenital Radiology after revised FIGO staging 2018.

Authors:  Lucia Manganaro; Yulia Lakhman; Nishat Bharwani; Benedetta Gui; Silvia Gigli; Valeria Vinci; Stefania Rizzo; Aki Kido; Teresa Margarida Cunha; Evis Sala; Andrea Rockall; Rosemarie Forstner; Stephanie Nougaret
Journal:  Eur Radiol       Date:  2021-04-14       Impact factor: 5.315

2.  Pelvic exenteration for colorectal and non-colorectal cancer: a comparison of perioperative and oncological outcome.

Authors:  Andreas Bogner; Johannes Fritzmann; Thilo Welsch; Christoph Kahlert; Benjamin Müssle; Johannes Huber; Jakob Dobroschke; Ulrich Bork; Steffen Wolk; Marius Distler; Jürgen Weitz
Journal:  Int J Colorectal Dis       Date:  2021-03-07       Impact factor: 2.571

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.